Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study

 

Listen to Cyndi Edwards, host of Streetwise Live!, speak with Algernon CEO Christopher J. Moreau, and ask two world-renowned psychedelic drug experts Professor David Nutt and Dr. Rick Strassman MD why DMT might work as a potential new stroke treatment.

Share via
Copy link
Powered by Social Snap